The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

Spectrum Pharma (SPPI) drops on cancer drug setback

 Oct 09, 2009 05:40 PM UTC
Return Risk
-61.83% MID
Tracked Blogger
Symbol Sentiment Start Return Closed
SPPI n/a

Graphic_arrow1 Via BloggingStocks:  

Filed under: Major movement, Bad news, Options, Technical Analysis

SPPI logoSpectrum Pharmaceutical (NASDAQ: SPPI - option chain) stock is trading lower today after the company received a Complete Response letter from the FDA regarding FUSILEV, its treatment for advanced metastatic colorectal cancer. The FDA said the company did not demonstrate that FUSILEV is non-inferior to leucovorin in its supplemental New Drug Application. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on SPPI.

This morning, SPPI opened at $4.98. So far today the stock has hit a high of $5.44 and a low of $4.82. As of 12:00, SPPI is trading at $5.12, down $1.09 (-17.6%). The chart for SPPI looks neutral.

Continue reading Spectrum Pharma (SPPI) drops on cancer drug setback

Spectrum Pharma (SPPI) drops on cancer drug setback originally appeared on BloggingStocks on Fri, 09 Oct 2009 12:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments



Add to digg
Add to del.icio.us
Add to Google
Add to StumbleUpon
Add to Facebook
Add to Reddit
Add to Technorati




 Graphic_website1 Read the rest of original post »



Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment



IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch